Unbound Cloxacillin Concentrations During Continuous Infusion
Recruiting
Phase 4
Interventional Study
Staphylococcal Infections
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 25 (estimated)
- Sponsor
- Emeli Månsson · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too hi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 18 years or older
* Treating physician has decided to start continuous infusion of cloxacillin
Exclusion Criteria:
* Unwilling or unable to provide written informed consent
Contacts
Karl-Johan Lindner, PhD
004621173000
CONTACT